Today: 19 July 2026
Salesforce stock drops 5% — Cramer calls it “really great” as Wall Street waits for Agentforce revenue
3 February 2026
1 min read

Salesforce stock drops 5% — Cramer calls it “really great” as Wall Street waits for Agentforce revenue

SAN FRANCISCO, February 3, 2026, 07:30 PST

Shares of Salesforce dipped over 5% Tuesday morning, slipping to $199.65. The cloud software giant remains under pressure even amid consistent upbeat chatter about its artificial intelligence offerings.

This shift is significant as investors rapidly adjust valuations of major software firms. AI features may win over users but not immediately boost revenue, and it’s that disconnect traders are racing to assess.

CNBC host Jim Cramer noted that the market is treating Salesforce and ServiceNow similarly, despite both companies “doing fabulously.” He described them as “really great” but said he’s willing to go along with the market’s verdict for now. Cramer highlighted “multiple compression,” meaning investors are valuing each dollar of earnings less than before. insidermonkey.com

The sell-off was widespread. ServiceNow shares dropped roughly 7% in early trading. Microsoft and Oracle also slipped, fueling concerns that investors are retreating from enterprise software.

Citizens maintained a Market Outperform rating on Salesforce, setting a $405 price target in a January 27 note. They highlighted that the company’s Agentforce segment surpassed $500 million in annual recurring revenue during the fiscal third quarter, marking a 330% increase year over year, Insider Monkey reported. Annual recurring revenue measures expected subscription sales each year.

Trefis noted that Salesforce appears more affordable based on its price-to-sales ratio, claiming the stock trades roughly 43% lower than it did a year ago on that measure. Price-to-sales compares a company’s market cap to its yearly revenue.

A Seeking Alpha analysis released Tuesday noted that Salesforce’s AI “agents” are being adopted faster than revenue growth reflects, suggesting a potential upside if usage translates into billed sales. It estimated Agentforce ARR at $540 million in the fiscal third quarter, a modest portion of Salesforce’s projected $41.5 billion full-year revenue. Seeking Alpha

Last week, Salesforce announced it landed a $5.6 billion, 10-year IDIQ contract with the U.S. Army. This framework lets the Army place orders over time, up to that ceiling. Kendall Collins, head of Missionforce and Government Cloud, said, “From recruiting to the tactical edge, Salesforce is equipping our forces.” The company also clarified the $5.6 billion figure isn’t a guaranteed purchase amount. Salesforce

Salesforce reported in its latest quarterly update that Agentforce and Data 360 annual recurring revenue hit nearly $1.4 billion, backed by more than 9,500 paid Agentforce deals. CEO Marc Benioff described these segments as key “momentum drivers,” while CFO Robin Washington outlined a target of surpassing $60 billion in organic revenue by fiscal 2030. Salesforce

Timing is the market’s main complaint. AI features might grab pilots and headlines, yet reported revenue can lag for quarters. Meanwhile, large government contracts don’t always lead to immediate spending — sometimes orders just don’t come through.

Salesforce is set to announce its earnings on Feb. 25, Nasdaq reports, offering investors an updated view on whether its AI investments are starting to pay off.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • CSL Recovers A$16 Billion in Value, Trails Plasma Sector Gains This Week
    July 19, 2026, 3:25 PM EDT. CSL Limited (ASX:CSL) finished July 17 at A$123.32, rising 1.12% on the session and 0.35% for the week, recovering 37% from its 52-week low at A$90 and regaining roughly A$16 billion in valuation. However, CSL underperformed plasma specialists Grifols SA (+1.95%) and Takeda Pharmaceutical (+2.26%) in weekly movement. Trading volume for CSL on Friday came in 14% under its average as 1.62 million shares changed hands. The full-year financial results are due August 18. Still 55% beneath its 52-week peak, CSL's market value stands at A$59.06 billion. The group forecasts FY26 revenues near US$15.2 billion and NPATA of about US$3.1 billion, while a US$5 billion impairment remains subject to audit and board sign-off.
British American Tobacco share price ticks up on fresh buyback notice as dividend, Feb 12 results near
Previous Story

British American Tobacco share price ticks up on fresh buyback notice as dividend, Feb 12 results near

Abbott (ABT) stock slips on FDA warning letter over FreeStyle Libre testing; dates to watch
Next Story

Abbott (ABT) stock slips on FDA warning letter over FreeStyle Libre testing; dates to watch

Go toTop